Search - tctmd.com

Displaying 41 - 60 of 99

Sort: Relevancy | Date

Presentation

Optimal Timing of an Invasive Strategy with NSTE ACS Patients

August 14, 2017

News Daily News

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Michael O'Riordan

August 14, 2017

News Daily News

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Michael O'Riordan

January 18, 2017

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

News Daily News

比伐卢定和普通肝素对有无 ST 段抬高的 ACS 患者没有任何差异：MATRIX

Shelley Wood

October 03, 2016

News Daily News

No Differences Between Bivalirudin, Unfractionated Heparin in ACS Patients With or Without ST Elevation: MATRIX

Shelley Wood

October 03, 2016

News Daily News

美国指南更新，将接受 DES 的稳定患者的 DAPT 持续时间从 12 个月下调为 6 个月

Yael L. Maxwell

March 30, 2016

News Daily News

Updated US Guidelines Lower DAPT Duration From 12 to 6 Months in Stable Patients Receiving DES

Yael L. Maxwell

March 30, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2016

Shelley Wood

February 01, 2016

News Daily News

导管室并发症：新的分析精准确定了 ACS 患者术中血栓事件的事件率及风险

Shelley Wood

January 21, 2016

News Daily News

Cath-Lab Complications: New Analysis Pinpoints Rate and Risks of Intraprocedural Thrombotic Events in ACS

Shelley Wood

January 21, 2016

News Daily News

在已有侵入性策略安排的NSTE-ACS患者中，上游比伐卢定的效果最好

L.A. McKeown

September 21, 2015

News Daily News

Upstream Bivalirudin Best in NSTE-ACS Patients With Planned Invasive Strategy

L.A. McKeown

September 21, 2015

Presentation

Impact of Anticoagulation Regimen Prior toRevascularization in Patients With NSTE-ACS

Presenter: Tobias Geisler

September 18, 2015

News Industry News

Medicure Announces Filing of sNDA for New AGGRASTAT® Indication

September 10, 2015

News Industry News

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

September 03, 2015

News Conference News ESC 2015

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

Yael L. Maxwell

September 02, 2015

News Conference News ESC 2015

Analyses Suggest Prasugrel Causes No Excess Bleeding in Stable CAD Patients

Caitlin E. Cox

August 31, 2015

Advertisement

Optimal Timing of an Invasive Strategy with NSTE ACS Patients

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

比伐卢定和普通肝素对有无 ST 段抬高的 ACS 患者没有任何差异：MATRIX

No Differences Between Bivalirudin, Unfractionated Heparin in ACS Patients With or Without ST Elevation: MATRIX

美国指南更新，将接受 DES 的稳定患者的 DAPT 持续时间从 12 个月下调为 6 个月

Updated US Guidelines Lower DAPT Duration From 12 to 6 Months in Stable Patients Receiving DES

TCTMD’s Top 10 Most Popular Stories for January 2016

导管室并发症：新的分析精准确定了 ACS 患者术中血栓事件的事件率及风险

Cath-Lab Complications: New Analysis Pinpoints Rate and Risks of Intraprocedural Thrombotic Events in ACS

在已有侵入性策略安排的NSTE-ACS患者中，上游比伐卢定的效果最好

Upstream Bivalirudin Best in NSTE-ACS Patients With Planned Invasive Strategy

Impact of Anticoagulation Regimen Prior toRevascularization in Patients With NSTE-ACS

Medicure Announces Filing of sNDA for New AGGRASTAT® Indication

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

Analyses Suggest Prasugrel Causes No Excess Bleeding in Stable CAD Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content